$XBI $132.57 +1%
Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$IBRX -1% Preliminary Phase 1b data reported. source
$MRNA +2% Publication of antibody persistence data out to 6 months following the second dose. source
Pipeline Updates
$ATOS -5% Expanded access treatment underway. source
$PRVB -41% FDA noted additional data would be required for BLA. source
$APRE +15% Eprenetapopt granted Orphan Drug Designation. source
$AUPH +2% Additional data from pivotal trial presented at SCM21. source
$RNLX +5% Presented data at SCM21. source
$GILD -1% FDA approval to Trodelvy®. source
Finance Updates
$KMPH -1% Amendment to the definitive collaboration and license agreement with GPC. source
$GLPG +1% Amendment to the share subscription agreement closed in 2019 with $GILD. source
$JAGX +3% Update to equity purchase agreement. source
$DRNA +3% Sold royalty rights for OXLUMO to $RPRX. source
Comments